FDA Approves New Targeted Therapy Doubling Survival in Metastatic Pancreatic Cancer

The U.S. Food and Drug Administration (FDA) has approved Rasonque (daraxonrasib), a new targeted treatment for adults with metastatic pancreatic adenocarcinoma harboring RAS mutations. This approval follows a large randomized clinical trial involving 500 patients, which demonstrated a median overall survival of 13.2 months for those treated with daraxonrasib, compared to 6.7 months for patients receiving standard chemotherapy. The drug, administered orally once daily, inhibits multiple active forms of RAS proteins, which play a key role in cell growth and division and are commonly mutated in pancreatic cancer.

Pancreatic cancer is notoriously difficult to treat and often diagnosed late due to a lack of specific symptoms. Approximately 90-95% of pancreatic cancer cases in the U.S. are adenocarcinomas, the subtype targeted by this new therapy. Common side effects reported include rash, diarrhea, mouth inflammation, nausea, fatigue, vomiting, abdominal pain, swelling, and appetite loss, with warnings for serious adverse effects requiring medical monitoring.

The FDA granted daraxonrasib accelerated development designations such as Breakthrough Therapy and Priority Review prior to approval. However, this FDA approval does not automatically authorize the drug's availability in Israel, where local registration and funding decisions will determine its accessibility. This advancement also highlights a broader shift in oncology towards treatments tailored to the molecular characteristics of tumors rather than solely their anatomical location, suggesting genomic testing may become increasingly important for pancreatic cancer treatment selection.